Vekerdy-Lakatos S, Lakatos L, Oroszlán G, Itzés B
Acta Paediatr Hung. 1987;28(1):9-16.
A prospective controlled trial has recently been reported to show the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP) among infants less than 2000 g birth-weight. The present paper is a comprehensive overview of a cohort of 204 prematures enrolled in the above study, with respect to mortality and outcome. Survival rate in the DPA treated group was the same as of those receiving conventional therapy. When the outcome of the DPA treated and the control infants was compared in terms of both major and minor impairments, the frequency of disabled and handicapped infants was higher in the control group. The same was observed with respect to the number of repeated hospital treatments, which was significantly higher among the control babies. The results suggest that DPA effectively prevents ROP among very-low-birth-weight infants, and also that the drug has no adverse effect on either mortality or late development.
最近有一项前瞻性对照试验报告显示，D-青霉胺（DPA）对预防出生体重低于2000克的婴儿发生早产儿视网膜病变（ROP）有效。本文全面概述了上述研究中纳入的204名早产儿队列的死亡率和结局情况。DPA治疗组的存活率与接受传统治疗的组相同。当比较DPA治疗组和对照组婴儿在主要和次要损伤方面的结局时，对照组中残疾和有缺陷婴儿的频率更高。在重复住院治疗次数方面也观察到同样情况，对照组婴儿的重复住院治疗次数明显更高。结果表明，DPA能有效预防极低出生体重婴儿发生ROP，而且该药物对死亡率或后期发育均无不良影响。
